Pacira BioSciences, Inc. Common Stock

PCRXNASDAQ • USD
36.38 USD
↘ 0.04 (0.11%)AT CLOSE (03:59 PM EDT)
36.78
↗ 0.40 (1.09%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
36.78
↗ 0.40 (1.09%)
🔴Market: CLOSED

Shares of Pacira BioSciences, Inc. Common Stock (PCRX) are trading at $36.39. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". This is driven by a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics suggest PCRX is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Oct 26, 2026.

Open?$36.38
High?$36.45
Low?$36.37
Prev. Close?$36.42
Volume?607.3K
Avg. Volume?1.9M
VWAP?$36.40
Rel. Volume?0.31x
Bid / Ask
Bid?$36.30 × 300
Ask?$36.57 × 300
Spread?$0.27
Midpoint?$36.44
Valuation & Ratios
Market Cap?1.5B
Shares Out?39.9M
Float?38.2M
Float %?95.8%
P/E Ratio?99.30
P/B Ratio?2.16
EPS?$0.37
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Employees
829
Market Cap
1.5B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2011-02-03
Address
2000 SIERRA POINT PARKWAY
BRISBANE, CA 94005
Phone: 650-242-8052
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
60
Z-Score?
51
Momentum?
43
Short Sent.?
83
Piotroski F-Score?5/9Mixed
Altman Z-Score?2.44Grey
Confidence?66%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?11.16%High
Short Interest?4.3M
Days to Cover?1.1
Free Float38.2M
Avg Daily Volume3.9M
Settlement Date2026-10-15
Financial Health
Current Ratio?5.07Strong
Quick Ratio?3.96Strong
Cash Ratio?1.70Strong
Debt/Equity?0.54Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
Peers
100
S&P
3
99.3PRICEY▾
P/B?
Peers
100
S&P
71
2.16CHEAP▾
P/S?
Peers
100
S&P
68
1.95CHEAP▾
P/FCF?
Peers
100
S&P
93
8.1CHEAP▾
EV/EBITDA?
Peers
100
S&P
48
15.2FAIR▾
EV/Sales?
Peers
100
S&P
72
2.16CHEAP▾
Returns & Efficiency
ROE?
Peers
50
S&P
17
2.2%WEAK▾
ROA?
Peers
50
S&P
13
1.2%WEAK▾
Cash Flow & Enterprise
FCF?$179.5M
Enterprise Value?$1.6B
Fundamentals ratios updated end of day